IP Library Granted Patent US 8,455,687
Granted Patent B2
US 8,455,687 · App. 13/010,023 · Granted Jun 4, 2013

Compounds and compositions for use as modulators of tau aggregation and alleviation of tauopathies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,455,687
App. No.
13/010,023
Granted
Jun 4, 2013
Kind
B2
Abstract

This invention relates to the use of bis- and tris-dihydroxyaryl compounds as well as sulfonamides, heteroaryls, tricycloalkyl and their analogs and pharmaceutically acceptable salts, for modulating tau aggregation and alleviating tauopathies, such as Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and familial frontotemporal dementia/Parkinsonism linked to chromosome 17 (FTDP-17), amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.

Claims (7)

1. A method of disrupting or causing the dissolution of tau aggregates in a mammal suffering from a tauopathy, comprising administering to the mammal suffering from a tauopathy an effective amount of compound 1,3-bis(3,4-dihydroxyphenyl)urea (compound DC-0076) and pharmaceutically acceptable salts thereof.

2. The method of claim 1 , wherein the amount of the compound administered is between 0.1 mg/Kg/day and 1000 mg/Kg/day.

3. The method of claim 1 , wherein the amount of compound administered is between 1 mg/Kg/day and 100 mg/Kg/day.

4. The method of claim 1 , wherein the amount of compound administered is between 10 mg/Kg/day and 100 mg/Kg/day.

5. The method of claim 1 , wherein the tauopathy is selected from the group consisting of Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, familial frontotemporal dementia/Parkinsonism linked to chromosome, amyotrophic lateral sclerosis /Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.

6. The method of claim 1 wherein the compound administered is administered by one of routes selected from, oral, topical, systemic or parenteral.

7. The method of claim 1 wherein the mammal is human.

Assignments (3)
CHANGE OF NAME Recorded Jun 9, 2016
From: PROTEOTECH, INC.
To: PROTAMED, INC.
Reel/Frame 038944/0598 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2013
From: CAM, JUDY
To: PROTEOTECH, INC.
Reel/Frame 030823/0616 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2011
From: SNOW, ALAN; HU, QUBAI; LAKE, THOMAS
To: PROTEOTECH INC.
Reel/Frame 026103/0648 →